Janssen Biotech ended development of its CD20/CD19 CAR T therapy, prizloncabtagene autoleucel (C-CAR039), transferring the program’s rights back to Abelzeta Pharma. Abelzeta previously had out-licensed global rights to Janssen, excluding China, under an earlier deal. The termination pauses Janssen’s CAR T direction in this specific product line and shifts development responsibilities back to Abelzeta, which is now positioned to decide next steps for the therapy’s clinical and regulatory plan. The change highlights how big pharma is continuously rebalancing CAR T pipelines based on trial performance, investment priorities and competitive positioning across oncology cell therapies.